Latinos and Hispanics Prone to Kidney Disease Gene Variant
By LabMedica International staff writers Posted on 21 Jan 2019 |
Image: The APOL1 G1 and G2 risk alleles in 111 global reference populations (Photo courtesy of the Icahn School of Medicine).
Risk variants in the apolipoprotein A-I (APOL1) gene on chromosome 22, which were first discovered in African Americans, confer a substantially increased risk of kidney disease, early-onset hypertension, and cardiovascular disease, although disease risk is modified by other genetic factors and by environmental factors.
However, other populations who also share recent ancestry from Africa, such as Hispanic populations, may be at greater risk than expected for APOL1-driven disease. These persons may not undergo testing; however, they may still be at high risk because of the presence of APOL1 risk variants. According to the National Kidney Association, about 10% of the world's population suffers from kidney disease.
Scientists at the Icahn School of Medicine at Mount Sinai (New York, NY, USA) and their colleagues used linked genetic and demographic data from 111 populations in two large studies, the Population Architecture using Genomics and Epidemiology Study and the Consortium on Asthma among African-ancestry Populations in the Americas, to determine the global frequencies of APOL1 risk variants. They inferred risk-allele status using the two G1 alleles (rs60910145 and rs73885319) and the proxy single-nucleotide polymorphism commonly typed for G2 (rs12106505).
The investigators found elevated frequencies of the APOL1 haplotype in African-American, sub-Saharan African, and Western African populations (11% to 32%). However, they also found other populations with elevated frequencies, including Jamaican, Barbadian, Grenadian, and Brazilian from Salvador (>10% to 22%); Trinidadian, Panamanian, Honduran, Haitian, Garifunan, and Palenque (>5% to 10%); and Guyanese, Dominican, Peruvian, Belizean, and Native American (1% to 5%). These findings show that the risk alleles are present in populations of persons who are not typically screened, which may result in the under diagnosis and under treatment of kidney disease and related coexisting conditions.
Girish Nadkarni, MD, MPH, an Assistant Professor of Medicine and study first author, said, “This finding is crucial in early detection of at-risk individuals who may not be indicated for genetic screening due to self-reporting of ethnic origins, but may still be at high risk due to the presence of APOL1 risk variants. It is important to more fully understand the global distribution of these variants based on country of origin and genetic ancestry rather than self-reported race/ethnic group.” The study was published on December 27, 2018, in the journal The New England Journal of Medicine.
Related Links:
Icahn School of Medicine at Mount Sinai
However, other populations who also share recent ancestry from Africa, such as Hispanic populations, may be at greater risk than expected for APOL1-driven disease. These persons may not undergo testing; however, they may still be at high risk because of the presence of APOL1 risk variants. According to the National Kidney Association, about 10% of the world's population suffers from kidney disease.
Scientists at the Icahn School of Medicine at Mount Sinai (New York, NY, USA) and their colleagues used linked genetic and demographic data from 111 populations in two large studies, the Population Architecture using Genomics and Epidemiology Study and the Consortium on Asthma among African-ancestry Populations in the Americas, to determine the global frequencies of APOL1 risk variants. They inferred risk-allele status using the two G1 alleles (rs60910145 and rs73885319) and the proxy single-nucleotide polymorphism commonly typed for G2 (rs12106505).
The investigators found elevated frequencies of the APOL1 haplotype in African-American, sub-Saharan African, and Western African populations (11% to 32%). However, they also found other populations with elevated frequencies, including Jamaican, Barbadian, Grenadian, and Brazilian from Salvador (>10% to 22%); Trinidadian, Panamanian, Honduran, Haitian, Garifunan, and Palenque (>5% to 10%); and Guyanese, Dominican, Peruvian, Belizean, and Native American (1% to 5%). These findings show that the risk alleles are present in populations of persons who are not typically screened, which may result in the under diagnosis and under treatment of kidney disease and related coexisting conditions.
Girish Nadkarni, MD, MPH, an Assistant Professor of Medicine and study first author, said, “This finding is crucial in early detection of at-risk individuals who may not be indicated for genetic screening due to self-reporting of ethnic origins, but may still be at high risk due to the presence of APOL1 risk variants. It is important to more fully understand the global distribution of these variants based on country of origin and genetic ancestry rather than self-reported race/ethnic group.” The study was published on December 27, 2018, in the journal The New England Journal of Medicine.
Related Links:
Icahn School of Medicine at Mount Sinai
Latest Pathology News
- Use of DICOM Images for Pathology Diagnostics Marks Significant Step towards Standardization
- First of Its Kind Universal Tool to Revolutionize Sample Collection for Diagnostic Tests
- AI-Powered Digital Imaging System to Revolutionize Cancer Diagnosis
- New Mycobacterium Tuberculosis Panel to Support Real-Time Surveillance and Combat Antimicrobial Resistance
- New Method Offers Sustainable Approach to Universal Metabolic Cancer Diagnosis
- Spatial Tissue Analysis Identifies Patterns Associated With Ovarian Cancer Relapse
- Unique Hand-Warming Technology Supports High-Quality Fingertip Blood Sample Collection
- Image-Based AI Shows Promise for Parasite Detection in Digitized Stool Samples
- Deep Learning Powered AI Algorithms Improve Skin Cancer Diagnostic Accuracy
- Microfluidic Device for Cancer Detection Precisely Separates Tumor Entities
- Virtual Skin Biopsy Determines Presence of Cancerous Cells
- AI Detects Viable Tumor Cells for Accurate Bone Cancer Prognoses Post Chemotherapy
- First Ever Technique Identifies Single Cancer Cells in Blood for Targeted Treatments
- Innovative Blood Collection Device Overcomes Common Obstacles Related to Phlebotomy
- Intra-Operative POC Device Distinguishes Between Benign and Malignant Ovarian Cysts within 15 Minutes
- Simple Skin Biopsy Test Detects Parkinson’s and Related Neurodegenerative Diseases